{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:21:56Z","timestamp":1790713316316,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01913-5","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:29:24Z","timestamp":1765470564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Concurrent detection of cognitive impairment and amyloid positivity with a multimodal machine learning-enabled digital cognitive assessment"],"prefix":"10.1186","volume":"17","author":[{"given":"Ali","family":"Jannati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Toro-Serey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Gomes-Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell E.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Showalter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Tobyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Pascual-Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"issue":"2","key":"1913_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health. 2022;7(2):e105\u201325.","journal-title":"Lancet Public Health"},{"key":"1913_CR2","unstructured":"National Institute on Aging. Alzheimer\u2019s Disease Fact Sheet. Available from: https:\/\/www.nia.nih.gov\/health\/alzheimers-disease-fact-sheet. Cited 23 Feb 2023."},{"issue":"1","key":"1913_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12877-025-05967-w","volume":"25","author":"N Salari","year":"2025","unstructured":"Salari N, Lotfi F, Abdolmaleki A, Heidarian P, Rasoulpoor S, Fazeli J, et al. The global prevalence of mild cognitive impairment in geriatric population with emphasis on influential factors: a systematic review and meta-analysis. BMC Geriatr. 2025;25(1):313.","journal-title":"BMC Geriatr"},{"issue":"1","key":"1913_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13195-023-01272-z","volume":"15","author":"S Mattke","year":"2023","unstructured":"Mattke S, Jun H, Chen E, Liu Y, Becker A, Wallick C. Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis. Alzheimers Res Ther. 2023;15(1):128.","journal-title":"Alzheimers Res Ther"},{"key":"1913_CR5","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association. 2022 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2022;18(4):700\u201389.","DOI":"10.1002\/alz.12638"},{"key":"1913_CR6","unstructured":"Food and Drug Administration (FDA). FDA. FDA. 2023. FDA Converts Novel Alzheimer\u2019s Disease Treatment to Traditional Approval. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. Cited 22 Jul 2023."},{"key":"1913_CR7","unstructured":"Center for Drug Evaluation and Research. FDA approves treatment for adults with Alzheimer\u2019s disease, FDA. 2024. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease. Cited 11 Feb 2025."},{"issue":"6","key":"1913_CR8","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/jgs.15837","volume":"67","author":"J Kulmala","year":"2019","unstructured":"Kulmala J, Ngandu T, Havulinna S, Lev\u00e4lahti E, Lehtisalo J, Solomon A, et al. The effect of multidomain lifestyle intervention on daily functioning in older people. J Am Geriatr Soc. 2019;67(6):1138\u201344.","journal-title":"J Am Geriatr Soc"},{"key":"1913_CR9","doi-asserted-by":"publisher","first-page":"765584","DOI":"10.3389\/fneur.2021.765584","volume":"12","author":"N Chowdhary","year":"2021","unstructured":"Chowdhary N, Barbui C, Anstey KJ, Kivipelto M, Barbera M, Peters R, et al. Reducing the risk of cognitive decline and dementia: WHO recommendations. Front Neurol. 2021;12:765584.","journal-title":"Front Neurol"},{"key":"1913_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.624125","author":"J Lehtisalo","year":"2021","unstructured":"Lehtisalo J, Palmer K, Mangialasche F, Solomon A, Kivipelto M, Ngandu T. Changes in lifestyle, behaviors, and risk factors for cognitive impairment in older persons during the first wave of the Coronavirus Disease 2019 pandemic in Finland: results from the FINGER study. Front Psychiatry. 2021. https:\/\/doi.org\/10.3389\/fpsyt.2021.624125.","journal-title":"Front Psychiatry"},{"issue":"4","key":"1913_CR11","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3233\/JAD-210331","volume":"82","author":"A Solomon","year":"2021","unstructured":"Solomon A, Handels R, Wimo A, Antikainen R, Laatikainen T, Lev\u00e4lahti E, et al. Effect of a multidomain lifestyle intervention on estimated dementia risk. J Alzheimers Dis. 2021;82(4):1461\u20136.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"1913_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13195-024-01482-z","volume":"16","author":"D Ornish","year":"2024","unstructured":"Ornish D, Madison C, Kivipelto M, Kemp C, McCulloch CE, Galasko D, et al. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer\u2019s disease: a randomized, controlled clinical trial. Alzheimers Res Ther. 2024;16(1):122.","journal-title":"Alzheimers Res Ther"},{"key":"1913_CR13","unstructured":"Livingston G, Huntley J, Liu KY, Costafreda SG, Selb\u00e6k G, Alladi S et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024;0(0). Available from: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(24)01296-0\/fulltext."},{"key":"1913_CR14","unstructured":"Commissioner O of the. FDA. FDA. 2025. FDA Clears First Blood Test Used in Diagnosing Alzheimer\u2019s Disease. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease. Ciwted 19 May 2025."},{"key":"1913_CR15","unstructured":"Beckman Coulter Receives FDA Breakthrough Device Designation for Alzheimer\u2019. s Disease Blood Test. Available from: httpss:\/\/www.beckmancoulter.com\/about-beckman-coulter\/newsroom\/press-releases\/2025\/q1\/2025-jan28-bec-receives-fda-breakthrough-device-designation. Cited 19 May 2025."},{"key":"1913_CR16","unstructured":"Quanterix, Breaking Ground in Alzheimer\u2019s Diagnosis. : Simoa\u00ae p-Tau 217 Blood Test Receives FDA Breakthrough Device Designation. Quanterix. 2024. Available from: https:\/\/www.quanterix.com\/breaking-ground-in-alzheimers-diagnosis-simoa-p-tau-217-blood-test-receives-fda-breakthrough-device-designation\/. Cited 19 May 2025."},{"key":"1913_CR17","unstructured":"Roche granted FDA Breakthrough. Device Designation for blood test to support earlier Alzheimer\u2019s disease diagnosis. Available from: https:\/\/www.roche.com\/media\/releases\/med-cor-2024-04-11. Cited 19 May 2025."},{"key":"1913_CR18","unstructured":"Spear Bio. FDA breakthrough device designation of novel pTau 217 blood test. Spear Bio. 2025. Available from: https:\/\/spear.bio\/blog\/2025\/01\/13\/spear-bio-secures-fda-breakthrough-device-designation-for-its-novel-ptau-217-blood-test-advancing-scalable-solutions-for-early-alzheimers-disease-diagnosis\/. Cited 19 May 2025."},{"issue":"4","key":"1913_CR19","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3233\/JAD-220096","volume":"87","author":"DJ Libon","year":"2022","unstructured":"Libon DJ, Swenson R, Lamar M, Price CC, Baliga G, Pascual-Leone A. The Boston process approach and digital neuropsychological assessment: past research and future directions. JAD. 2022;87(4):1419\u201332.","journal-title":"JAD"},{"key":"1913_CR20","doi-asserted-by":"publisher","first-page":"1280593","DOI":"10.3389\/fpsyg.2023.1280593","volume":"14","author":"DJ Libon","year":"2023","unstructured":"Libon DJ, Matusz EF, Cosentino S, Price CC, Swenson R, Vermeulen M, et al. Using digital assessment technology to detect neuropsychological problems in primary care settings. Front Psychol. 2023;14:1280593.","journal-title":"Front Psychol"},{"key":"1913_CR21","doi-asserted-by":"publisher","first-page":"1415629","DOI":"10.3389\/fpsyg.2024.1415629","volume":"15","author":"DJ Libon","year":"2024","unstructured":"Libon DJ, Swenson R, Price CC, Lamar M, Cosentino S, Bezdicek O, et al. Digital assessment of cognition in neurodegenerative disease: a data driven approach leveraging artificial intelligence. Front Psychol. 2024;15:1415629.","journal-title":"Front Psychol"},{"key":"1913_CR22","doi-asserted-by":"publisher","first-page":"e66695","DOI":"10.2196\/66695","volume":"9","author":"AJ Doerr","year":"2025","unstructured":"Doerr AJ, Orwig TA, McNulty M, Sison SDM, Paquette DR, Leung R, et al. Digital assessment of cognitive health in outpatient primary care: usability study. JMIR Form Res. 2025;9:e66695.","journal-title":"JMIR Form Res"},{"issue":"1","key":"1913_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-023-01367-7","volume":"16","author":"A Jannati","year":"2024","unstructured":"Jannati A, Toro-Serey C, Gomes-Osman J, Banks R, Ciesla M, Showalter J, et al. Digital clock and recall is superior to the Mini-Mental state examination for the detection of mild cognitive impairment and mild dementia. Alz Res Ther. 2024;16(1):2.","journal-title":"Alz Res Ther"},{"issue":"1","key":"1913_CR24","volume":"16","author":"R Banks","year":"2024","unstructured":"Banks R, Higgins C, Greene BR, Jannati A, Gomes-Osman J, Tobyne S, et al. Clinical classification of memory and cognitive impairment with multimodal digital biomarkers. Alzheimers Dement Diagn Assess Dis Monit. 2024;16(1):e12557.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"key":"1913_CR25","doi-asserted-by":"publisher","first-page":"1337851","DOI":"10.3389\/fnhum.2024.1337851","volume":"18","author":"J Gomes-Osman","year":"2024","unstructured":"Gomes-Osman J, Borson S, Toro-Serey C, Banks R, Ciesla M, Jannati A, et al. Digital clock and recall: a digital, process-driven evolution of the Mini-Cog. Front Hum Neurosci. 2024;18:1337851.","journal-title":"Front Hum Neurosci"},{"issue":"S5","key":"1913_CR26","doi-asserted-by":"publisher","first-page":"e063676","DOI":"10.1002\/alz.063676","volume":"18","author":"DW Beauregard","year":"2022","unstructured":"Beauregard DW, Mohs R, Dwyer J, Hollingshead S, Smith K, Bork J, et al. Bio-Hermes: A validation study to assess a meaningful relationship between blood and digital biomarkers with A\u03b2 PET scans for alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2022;18(S5):e063676.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1913_CR27","doi-asserted-by":"crossref","unstructured":"Mohs RC, Beauregard D, Dwyer J, Gaudioso J, Bork J, MaGee-Rodgers T et al. The Bio\u2010Hermes Study: Biomarker database developed to investigate blood\u2010based and digital biomarkers in community\u2010based, diverse populations clinically screened for Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2024;alz.13722.","DOI":"10.1002\/alz.13722"},{"issue":"11","key":"1913_CR28","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6","volume":"15","author":"S Borson","year":"2000","unstructured":"Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive vital signs measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15(11):1021\u20137.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1913_CR29","unstructured":"Schmidt M. Rey auditory verbal learning test: A handbook. Volume 17. Western Psychological Services Los Angeles, CA; 1996."},{"issue":"1","key":"1913_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5498\/wjp.v10.i1.1","volume":"10","author":"D Cahn-Hidalgo","year":"2020","unstructured":"Cahn-Hidalgo D, Estes PW, Benabou R. Validity, reliability, and psychometric properties of a computerized, cognitive assessment test (Cognivue\u00ae). WJP. 2020;10(1):1\u201311.","journal-title":"WJP"},{"issue":"3","key":"1913_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10994-015-5529-5","volume":"102","author":"W Souillard-Mandar","year":"2016","unstructured":"Souillard-Mandar W, Davis R, Rudin C, Au R, Libon DJ, Swenson R, et al. Learning classification models of cognitive conditions from subtle behaviors in the digital clock drawing test. Mach Learn. 2016;102(3):393\u2013441.","journal-title":"Mach Learn"},{"key":"1913_CR32","doi-asserted-by":"crossref","unstructured":"Souillard-Mandar W, Penney D, Schaible B, Pascual-Leone A, Au R, Davis R, DCTclock. Clinically-Interpretable and Automated Artificial Intelligence Analysis of Drawing Behavior for Capturing Cognition. Frontiers in Digital Health. 2021;3:750661.","DOI":"10.3389\/fdgth.2021.750661"},{"issue":"1","key":"1913_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3233\/JAD-191089","volume":"75","author":"C Dion","year":"2020","unstructured":"Dion C, Arias F, Amini S, Davis R, Penney D, Libon DJ, et al. Cognitive correlates of digital clock drawing metrics in older adults with and without mild cognitive impairment. J Alzheimers Dis. 2020;75(1):73\u201383.","journal-title":"J Alzheimers Dis"},{"key":"1913_CR34","doi-asserted-by":"crossref","unstructured":"Davoudi A, Dion C, Amini S, Tighe PJ, Price CC, Libon DJ, et al. Classifying non-dementia and Alzheimer\u2019s disease\/vascular dementia patients using kinematic, time-based, and visuospatial parameters: the digital clock drawing test. JAD. 2021;82(1):47\u201357.","DOI":"10.3233\/JAD-201129"},{"issue":"14","key":"1913_CR35","doi-asserted-by":"publisher","first-page":"e1844","DOI":"10.1212\/WNL.0000000000011697","volume":"96","author":"DM Rentz","year":"2021","unstructured":"Rentz DM, Papp KV, Mayblyum DV, Sanchez JS, Klein H, Souillard-Mandar W, et al. Association of digital clock drawing with PET amyloid and Tau pathology in normal older adults. Neurology. 2021;96(14):e1844\u201354.","journal-title":"Neurology"},{"issue":"6","key":"1913_CR36","doi-asserted-by":"publisher","first-page":"e27407","DOI":"10.2196\/27407","volume":"23","author":"J Yuan","year":"2021","unstructured":"Yuan J, Libon DJ, Karjadi C, Ang AFA, Devine S, Auerbach SH, et al. Association between the digital clock drawing test and neuropsychological test performance: large community-based prospective cohort (Framingham heart Study). J Med Internet Res. 2021;23(6):e27407.","journal-title":"J Med Internet Res"},{"key":"1913_CR37","doi-asserted-by":"publisher","DOI":"10.1017\/S1355617722000091","author":"EF Matusz","year":"2022","unstructured":"Matusz EF, Price CC, Lamar M, Swenson R, Au R, Emrani S, et al. Dissociating statistically determined normal cognitive abilities and mild cognitive impairment subtypes with DCTclock. J Int Neuropsychol Soc. 2022. https:\/\/doi.org\/10.1017\/S1355617722000091.","journal-title":"J Int Neuropsychol Soc"},{"key":"1913_CR38","doi-asserted-by":"publisher","unstructured":"Fu JF, Robinson TL, Alonso MR, Malave AF, Jutten RJ, Properzi MJ, et al. Higher amyloid and tau burden is associated with faster decline on a digital cognitive test. Ann Clin Transl Neurol. 2025. Online ahead of print. https:\/\/doi.org\/10.1002\/acn3.70233.","DOI":"10.1002\/acn3.70233"},{"key":"1913_CR39","doi-asserted-by":"crossref","unstructured":"Ding H, Lyu C, Karjadi C, Sunderaraman P, Young CB, Mormino EC et al. Association of the digital clock drawing test with amyloid and tau PET biomarkers in low age risk adults. Sci Rep. 2025;15(1). Available from: https:\/\/www.nature.com\/articles\/s41598-025-95852-8.","DOI":"10.1038\/s41598-025-95852-8"},{"key":"1913_CR40","unstructured":"Keszycki R, Dion C, Prieto S, Emrani S, Au R. Digital clock drawing performance is associated with neuroimaging biomarkers of alzheimer\u2019s disease and cerebrovascular disease in cognitively healthy older adults. International neuropsychological society. New Orleans, USA; 2025."},{"key":"1913_CR41","doi-asserted-by":"crossref","unstructured":"Hammers D, Fowler N, Brosch J, Swartzell K, Banks R, Jannati A et al. Comparative performance of the Digital Clock and Recall (DCR\u2122) Test, Montreal Cognitive Assessment (MoCA), and Saint Louis University Mental Status (SLUMS) among patients in primary care. In: Alzheimer\u2019s Association International Conference (AAIC). Amsterdam, Netherlands; 2023.","DOI":"10.1002\/alz.079034"},{"issue":"S5","key":"1913_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/alz.087555","volume":"20","author":"D Summanwar","year":"2024","unstructured":"Summanwar D, Brosch JR, Hammers DB, Fowler NR, Willis DR. Optimizing primary care for cognitive impairment screening using agile implementation. Alzheimers Dement. 2024;20(S5):e087555.","journal-title":"Alzheimers Dement"},{"issue":"S5","key":"1913_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/alz.087937","volume":"20","author":"T MacLeod","year":"2024","unstructured":"MacLeod T, Murray JF, Dos Santos Filho OC, De S\u00e1 Paiva Lima MD, Govia I, Robinson J, et al. Implementing digital cognitive assessments to detect cognitive impairment: results from the Davos alzheimer\u2019s collaborative early detection program. Alzheimers Dement. 2024;20(S5):e087937.","journal-title":"Alzheimers Dement"},{"key":"1913_CR44","doi-asserted-by":"crossref","unstructured":"Summanwar D, Fowler NR, Hammers DB, Perkins AJ, Brosch JR, Willis DR. Agile implementation of a digital cognitive assessment for dementia in primary care. Ann Fam Med. 2025;240294.","DOI":"10.1370\/afm.240294"},{"key":"1913_CR45","doi-asserted-by":"crossref","unstructured":"Fowler NR, Hammers DB, Perkins AJ, Summanwar D, Higbie A, Swartzell K et al. Feasibility and acceptability of implementing a digital cognitive assessment for alzheimer disease and related dementias in primary care. Ann Fam Med. 2025;240293.","DOI":"10.1370\/afm.240293"},{"key":"1913_CR46","doi-asserted-by":"crossref","unstructured":"Ozawa T, Selzler KJ, Ball DE, Deckert A, MacLeod T, Corr\u00eaa Dos Santos Filho O et al. Effects of the Davos alzheimer\u2019s collaborative early detection of cognitive impairment program on clinician attitudes, engagement, and confidence. J Prev Alzheimer\u2019s Disease. 2025;100038.","DOI":"10.1016\/j.tjpad.2024.100038"},{"key":"1913_CR47","doi-asserted-by":"publisher","unstructured":"Fedorov A, Saurman J, Ro J, Ammar Abdulraheem Ahmed J, Edwards P, Loring D et al. Digital Clock Drawing and Recall Enables Rapid Cognitive Screening in Acute Ischemic Stroke Care. Stroke. 2025;56(Suppl_1). Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/str.56.suppl_1.TP28. Cited 28 Mar 2025.","DOI":"10.1161\/str.56.suppl_1.TP28"},{"key":"1913_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-025-09702-4","author":"DB Hammers","year":"2025","unstructured":"Hammers DB, Schulman D, Fowler NR, Musema J, Brosch JR, Summanwar D, et al. Performance of older adults on the digital clock and recall test compared to the Montreal Cognitive Assessment in primary care settings. J Gen Intern Med. 2025. https:\/\/doi.org\/10.1007\/s11606-025-09702-4. Cited 9 Jul 2025.","journal-title":"J Gen Intern Med"},{"key":"1913_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.3599","author":"ME Belloy","year":"2023","unstructured":"Belloy ME, Andrews SJ, Le Guen Y, Cuccaro M, Farrer LA, Napolioni V, et al. APOE genotype and Alzheimer disease risk across age, sex, and population ancestry. JAMA Neurol. 2023. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3599. Cited 7 Dec 2023.","journal-title":"JAMA Neurol"},{"key":"1913_CR50","doi-asserted-by":"crossref","unstructured":"Wolk DA, Dickerson BC, the Alzheimer\u2019s Disease Neuroimaging Initiative, Weiner M, Aiello M, Aisen P et al. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer\u2019s disease. Proceedings of the National Academy of Sciences. 2010;107(22):10256\u201361.","DOI":"10.1073\/pnas.1001412107"},{"issue":"10","key":"1913_CR51","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/acn3.51863","volume":"10","author":"M Monane","year":"2023","unstructured":"Monane M, Johnson KG, Snider BJ, Turner RS, Drake JD, Maraganore DM, et al. A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment. Ann Clin Transl Neurol. 2023;10(10):1738\u201348.","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"1913_CR52","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma Phospho-tau217 for alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772\u201381.","journal-title":"JAMA"},{"issue":"5","key":"1913_CR53","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated Tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1913_CR54","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging \u03b2-amyloid pathology. JAMA. 2011;305(3):275\u201383.","journal-title":"JAMA"},{"issue":"2","key":"1913_CR55","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.neuroimage.2009.09.069","volume":"49","author":"R Wolz","year":"2010","unstructured":"Wolz R, Aljabar P, Hajnal JV, Hammers A, Rueckert D. Alzheimer\u2019s disease neuroimaging Initiative. LEAP: learning embeddings for atlas propagation. Neuroimage. 2010;49(2):1316\u201325.","journal-title":"Neuroimage"},{"key":"1913_CR56","doi-asserted-by":"publisher","unstructured":"Grecchi E, Foley C, Gispert JD, Wolz R, Suvr analysis using the supratentorial white matter as reference region. P3-434: Centiloid PET. Alzheimer\u2019s & Dementia. 2018;14(7S_Part_24). Available from: https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1016\/j.jalz.2018.06.1797. Cited 26 Aug 2023.","DOI":"10.1016\/j.jalz.2018.06.1797"},{"issue":"23","key":"1913_CR57","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1002\/sim.4509","volume":"31","author":"X Liu","year":"2012","unstructured":"Liu X. Classification accuracy and cut point selection. Stat Med. 2012;31(23):2676\u201386.","journal-title":"Stat Med"},{"key":"1913_CR58","first-page":"2825","volume":"12","author":"F Pedregosa","year":"2011","unstructured":"Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12:2825\u201330.","journal-title":"J Mach Learn Res"},{"issue":"12","key":"1913_CR59","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(12):2669\u201386.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"1913_CR60","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","volume":"4","author":"J Therriault","year":"2024","unstructured":"Therriault J, Janelidze S, Benedet AL, Ashton NJ, Arranz Mart\u00ednez J, Gonzalez-Escalante A, et al. Diagnosis of Alzheimer\u2019s disease using plasma biomarkers adjusted to clinical probability. Nat Aging. 2024;4(11):1529\u201337.","journal-title":"Nat Aging"},{"issue":"S24","key":"1913_CR61","doi-asserted-by":"publisher","first-page":"e082822","DOI":"10.1002\/alz.082822","volume":"19","author":"CT Udeh-Momoh","year":"2023","unstructured":"Udeh-Momoh CT, Mielke MM, Schindler SE, Hansson O, Khachaturian AS, Weiss J. Bridging the gap: the global CEOi collaborative workgroup for adoption of alzheimer\u2019s disease Blood\u2010Based biomarkers in clinical practice. Alzheimer\u2019s Dement. 2023;19(S24):e082822.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1913_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-024-00977-5","author":"SE Schindler","year":"2024","unstructured":"Schindler SE, Galasko D, Pereira AC, Rabinovici GD, Salloway S, Su\u00e1rez-Calvet M, et al. Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the global CEO initiative on alzheimer\u2019s disease. Nat Rev Neurol. 2024. https:\/\/doi.org\/10.1038\/s41582-024-00977-5.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1913_CR63","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1212\/WNL.0000000000207393","volume":"101","author":"P Diaz-Galvan","year":"2023","unstructured":"Diaz-Galvan P, Przybelski SA, Lesnick TG, Schwarz CG, Senjem ML, Gunter JL, et al. \u03b2-amyloid load on PET along the continuum of dementia with lewy bodies. Neurology. 2023;101(2):e178-88.","journal-title":"Neurology"},{"key":"1913_CR64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.dadm.2017.05.005","volume":"9","author":"RH Tan","year":"2017","unstructured":"Tan RH, Kril JJ, Yang Y, Tom N, Hodges JR, Villemagne VL, et al. Assessment of amyloid \u03b2 in pathologically confirmed frontotemporal dementia syndromes. Alzheimers Dement (Amst). 2017;9:10\u201320.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"19","key":"1913_CR65","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1212\/WNL.0000000000003197","volume":"87","author":"ME Gurol","year":"2016","unstructured":"Gurol ME, Becker JA, Fotiadis P, Riley G, Schwab K, Johnson KA, et al. Florbetapir-PET to diagnose cerebral amyloid angiopathy: a prospective study. Neurology. 2016;87(19):2043\u20139.","journal-title":"Neurology"},{"issue":"1","key":"1913_CR66","doi-asserted-by":"publisher","first-page":"16665","DOI":"10.1038\/s41598-020-73673-1","volume":"10","author":"S Haller","year":"2020","unstructured":"Haller S, Montandon ML, Lilja J, Rodriguez C, Garibotto V, Herrmann FR, et al. PET amyloid in normal aging: direct comparison of visual and automatic processing methods. Sci Rep. 2020;10(1):16665.","journal-title":"Sci Rep"},{"issue":"10","key":"1913_CR67","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/NEN.0b013e31822e8ae9","volume":"70","author":"KS SantaCruz","year":"2011","unstructured":"SantaCruz KS, Sonnen JA, Pezhouh MK, Desrosiers MF, Nelson PT, Tyas SL. Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun study and the adult changes in thought study. J Neuropathol Exp Neurol. 2011;70(10):832\u201340.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"8","key":"1913_CR68","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of alzheimer\u2019s disease: alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"1913_CR69","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer disease as a clinical-biological construct\u2014an international working group recommendation. JAMA Neurol. 2024;81(12):1304.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1913_CR70","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S1474-4422(23)00447-7","volume":"23","author":"GB Frisoni","year":"2024","unstructured":"Frisoni GB, Festari C, Massa F, Ramusino MC, Orini S, Aarsland D, et al. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. Lancet Neurol. 2024;23(3):302\u201312.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1913_CR71","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/13872877241290123","volume":"102","author":"M Ciesla","year":"2024","unstructured":"Ciesla M, Toro-Serey C, Jannati A, Banks RE, Gomes-Osman J, Showalter J, et al. Detecting functional impairment with the digital clock and recall. J Alzheimers Dis. 2024;102(2):329\u201337.","journal-title":"J Alzheimers Dis"},{"key":"1913_CR72","doi-asserted-by":"publisher","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S et al. Lecanemab: Appropriate Use Recommendations. J Prev Alz Dis. 2023; Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.14283\/jpad.2023.30. Cited 25 Jul 2023.","DOI":"10.14283\/jpad.2023.30"},{"key":"1913_CR73","doi-asserted-by":"publisher","unstructured":"Pittock RR, Aakre J, Castillo AM, Ramanan VK, Kremers WK, Jack CR et al. Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging. Neurology. 2023; Available from: https:\/\/www.neurology.org\/lookup\/doi\/https:\/\/doi.org\/10.1212\/WNL.0000000000207770. Cited 23 Aug 2023.","DOI":"10.1212\/WNL.0000000000207770"},{"issue":"9","key":"1913_CR74","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S, Ashton NJ, Zimmer ER, Therriault J, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging. 2023;3(9):1079\u201390.","journal-title":"Nat Aging"},{"issue":"5","key":"1913_CR75","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.14283\/jpad.2024.110","volume":"11","author":"M Manjavong","year":"2024","unstructured":"Manjavong M, Kang JM, Diaz A, Ashford MT, Eichenbaum J, Aaronson A, et al. Performance of plasma biomarkers combined with structural MRI to identify candidate participants for Alzheimer\u2019s Disease-Modifying therapy. J Prev Alzheimers Dis. 2024;11(5):1198\u2013205.","journal-title":"J Prev Alzheimers Dis"},{"key":"1913_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105345","volume":"108","author":"A Cano","year":"2024","unstructured":"Cano A, Capdevila M, Puerta R, Arranz J, Montrreal L, de Rojas I, et al. Clinical value of plasma pTau181 to predict Alzheimer\u2019s disease pathology in a large real-world cohort of a memory clinic. EBioMedicine. 2024;108:105345.","journal-title":"EBioMedicine"},{"issue":"1","key":"1913_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, Rodr\u00edguez-Baz \u00cd, Ferrer R, Carmona-Iragui M, et al. Diagnostic performance of plasma pTau217, pTau181, A\u03b21\u201342 and A\u03b21\u201340 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res Ther. 2024;16(1):139.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"1913_CR78","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/biom14010093","volume":"14","author":"G Garcia-Escobar","year":"2024","unstructured":"Garcia-Escobar G, Manero RM, Fern\u00e1ndez-Lebrero A, Ois A, Navalpotro-G\u00f3mez I, Puente-Periz V, et al. Blood biomarkers of Alzheimer\u2019s disease and cognition: a literature review. Biomolecules. 2024;14(1):93.","journal-title":"Biomolecules"},{"issue":"3","key":"1913_CR79","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/alz.12450","volume":"18","author":"JL Cummings","year":"2022","unstructured":"Cummings JL, Goldman DP, Simmons-Stern NR, Ponton E. The costs of developing treatments for Alzheimer\u2019s disease: a retrospective exploration. Alzheimers Dement. 2022;18(3):469\u201377.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1913_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12295","volume":"8","author":"J Cummings","year":"2022","unstructured":"Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, et al. Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8(1):e12295.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"10","key":"1913_CR81","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1038\/s41380-021-01263-2","volume":"26","author":"M Bucci","year":"2021","unstructured":"Bucci M, Chiotis K, Nordberg A, Alzheimer\u2019s disease neuroimaging Initiative. Alzheimer\u2019s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol Psychiatry. 2021;26(10):5888\u201398.","journal-title":"Mol Psychiatry"},{"issue":"3","key":"1913_CR82","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A, Strom A, Wang P, Iaccarino L, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387\u201397.","journal-title":"Nat Med"},{"issue":"1","key":"1913_CR83","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood\u2010based biomarkers for Alzheimer\u2019s disease. EMBO Mol Med. 2022;14(1):e14408.","journal-title":"EMBO Mol Med"},{"issue":"5","key":"1913_CR84","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/brain\/awad112","volume":"146","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Palmqvist S. The emerging era of staging Alzheimer\u2019s disease pathology using plasma biomarkers. Brain. 2023;146(5):1740\u20132.","journal-title":"Brain"},{"key":"1913_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101699","volume":"81","author":"RX Li","year":"2022","unstructured":"Li RX, Ma YH, Tan L, Yu JT. Prospective biomarkers of Alzheimer\u2019s disease: a systematic review and meta-analysis. Ageing Res Rev. 2022;81:101699.","journal-title":"Ageing Res Rev"},{"issue":"4","key":"1913_CR86","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/alz.12751","volume":"19","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist S, Stomrud E, Cullen N, Janelidze S, Manuilova E, Jethwa A, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2023;19(4):1204\u201315.","journal-title":"Alzheimer's & Dementia"},{"issue":"4","key":"1913_CR87","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1212\/WNL.0000000000207193","volume":"101","author":"D Alcolea","year":"2023","unstructured":"Alcolea D, Beeri MS, Rojas JC, Gardner RC, Lle\u00f3 A. Blood biomarkers in neurodegenerative diseases: implications for the clinical neurologist. Neurology. 2023;101(4):172\u201380.","journal-title":"Neurology"},{"key":"1913_CR88","doi-asserted-by":"crossref","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging Initiative, et al. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034\u201342.","DOI":"10.1038\/s41591-021-01348-z"},{"issue":"1","key":"1913_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00843-y","volume":"20","author":"AA Belaidi","year":"2025","unstructured":"Belaidi AA, Bush AI, Ayton S. Apolipoprotein E in Alzheimer\u2019s disease: molecular insights and therapeutic opportunities. Mol Neurodegener. 2025;20(1):47.","journal-title":"Mol Neurodegener"},{"key":"1913_CR90","unstructured":"Global Alzheimer\u2019s Platform. Bio-Hermes study. Available from: https:\/\/globalalzplatform.org\/biohermesstudy\/. Cited 11 May 2022."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01913-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01913-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01913-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:02:52Z","timestamp":1779260572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01913-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1913"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01913-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6768373\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and its later amendments. The study procedures were explained to participants verbally and through written informed consent that was approved by the local IRB of each site participating in the GAP consortium (see the Bio-Hermes study website [\n                      \n                      ] for a list of study sites). If, in the opinion of the site principal investigator, the participant did not have the capacity to sign the informed consent form, a legally authorized representative was used to grant consent on behalf of the participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AJ, KT, CTS, CH, JS, and ST are employees of Linus Health and declare ownership of shares or share options in the company. DB is a co-founder of Linus Health and declares ownership of shares or share options in the company. APL is a co-founder of Linus Health and declares ownership of shares or share options in the company. APL serves as a paid member of the scientific advisory boards for Neuroelectrics, Magstim Inc., TetraNeuron, AscenZion, Bitbrain, Skin2Neuron, and MedRhythms. The authors are listed as inventors on pending patents related to digital biomarkers of cognitive, functional, and amyloid PET status.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}